🔎 Trials Near Me

Home › Muscle Weakness › NCT05929755

Depo-Medrol on Psoas After LLIF

RecruitingPhase 4

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness

Who can join

Ages 18 to 75 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Patients from the practices of Drs. Singh, Mallozzi, Moss
* Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
* Patients who agree to be a part of the study
* Patients with lumbar disc degeneration
* Patients between ages of 18 and 75

Exclusion Criteria:

* Scoliosis \>10°
* Spondylolisthesis \>Grade 1
* Flatback deformity
* Patients with insulin dependent diabetes
* Patients with \>3 levels of fusion
* Alternative interbodies
* Chronic oral steroid users
* Patients with allergy/intolerance to depo-medrol or other steroids
* Patients requiring bilateral transpsoas approaches
* Patients with ipsilateral symptomatic hip pathology
* Revision fusion procedures
* Cases involving trauma, tumor, or infection
* Patient's not capable of providing consent themselves
* Non-fluent English speakers (for consenting reasons)
* Patients who are lost to follow-up before the two year follow up period

About the study

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

What is being tested

Sponsor: Hardeep Singh · Participants: 80 · Started: May 12, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05929755

Locations in the U.S.

ConnecticutUConn Health, Farmington

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.